ABTI
Alterola Biotech, Inc. [ABTI] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ABTI Stock Summary
In the News
ABTI Financial details
Company Rating
Sell
Market Cap
7.47M
Income
-1.2M
Revenue
0
Book val./share
-0
Cash/share
0
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
01 Jun 2024
P/E
-2.01
Forward P/E
-
PEG
0.25
P/S
-
P/B
-1.19
P/C
-
P/FCF
-4.59
Quick Ratio
-
Current Ratio
0.08
Debt / Equity
-0.77
LT Debt / Equity
-
-
-
EPS (TTM)
-0
EPS next Y
-
EPS next Q
-
EPS this Y
-77.38%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-77.78%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-241%
ROE
-17%
ROC
0.65%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.0012-0.0476
52W High
-
52W Low
-
RSI
59.27
Rel Volume
3.25
Avg Volume
5.85K
Volume
19K
Perf Week
36.71%
Perf Month
47.14%
Perf Quarter
-
Perf Half Y
35%
-
-
-
-
Beta
-0.099
-
-
Volatility
0%, 0%
Prev Close
0%
Price
0.0054
Change
0%
ABTI Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
| Metric | History | 2018-09-30 | 2019-09-30 | 2020-09-30 | 2022-03-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | 0 | 0 | 0 | -0.01 | 0 | |
| Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Cash per share | 0 | 0 | 0 | 0 | 0 | |
| Book value per share | 0 | 0 | 0 | 0.01 | 0.01 | |
| Tangible book value per share | 0 | 0 | 0 | 0 | 0 | |
| Share holders equity per share | 0 | 0 | 0 | 0.01 | 0.01 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 144.52M | 142.21M | 83.82M | 169.39M | 35.24M | |
| Enterprise value | 144.54M | 142.21M | 83.82M | 169.49M | 36.64M | |
| P/E ratio | -1.09K | -549.7 | -488.74 | -26.18 | -22.84 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -7.24K | 0 | 0 | 3.82K | -33.89 | |
| PFCF ratio | -7.24K | 0 | 0 | 3.82K | -29.87 | |
| P/B Ratio | -2.6K | -701.53 | -259.34 | 15.5 | 3.49 | |
| PTB ratio | -2.6K | -701.53 | -259.34 | 15.5 | 3.49 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -1.18K | -550.22 | -334.62 | -26.19 | -21.59 | |
| EV to operating cash flow | -7.25K | 0 | 0 | 3.82K | -35.24 | |
| EV to free cash flow | -7.25K | 0 | 0 | 3.82K | -31.06 | |
| Earnings yield | 0 | 0 | 0 | -0.04 | -0.04 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | -0.03 | |
| Debt to equity | -0.36 | 0 | 0 | 0.02 | 0.14 | |
| Debt to assets | 0.39 | 0 | 0 | 0.01 | 0.11 | |
| Net debt to EBITDA | -0.16 | 0 | 0 | -0.02 | -0.83 | |
| Current ratio | 0.59 | 0.07 | 0.05 | 0.11 | 0.11 | |
| Interest coverage | -11.66 | -1.04K | 0 | -6.47M | 9.48 | |
| Income quality | 0.15 | 0 | 0 | -0.01 | 0.6 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0.99 | 0.98 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0.13 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | -1.02 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0 | 0.01 | 0.01 | 0.05 | 0.02 | |
| ROIC | 3.44 | 1.27 | 0.7 | -0.58 | -0.15 | |
| Return on tangible assets | -2.62 | -17.55 | -11.23 | -50.57 | -6.5 | |
| Graham Net | 0 | 0 | 0 | 0 | 0 | |
| Working capital | -35.62K | -202.71K | -323.22K | -1.07M | -1.89M | |
| Tangible asset value | -55.57K | -202.71K | -323.22K | -1.07M | -2.04M | |
| Net current asset value | -55.57K | -202.71K | -323.22K | -1.07M | -2.04M | |
| Invested capital | -0.36 | 0 | 0 | 0.02 | 0.14 | |
| Average receivables | 0 | 0 | 0 | 25.34K | 44.32K | |
| Average payables | 12.12K | 12.12K | 0 | 271.26K | 577.16K | |
| Average inventory | 0 | 0 | 0 | 525 | 1.02K | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 2.39 | 1.28 | 0.53 | -0.59 | -0.15 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q2
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | 0 | 0 | 0 | 0 | 0 | |
| Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Cash per share | 0 | 0 | 0 | 0 | 0 | |
| Book value per share | 0.01 | 0.01 | 0.01 | 0.01 | 0 | |
| Tangible book value per share | 0 | 0 | 0 | 0 | 0 | |
| Share holders equity per share | 0.01 | 0.01 | 0.01 | 0.01 | 0 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 42.93M | 40.35M | 35.18M | 11.54M | 7.12M | |
| Enterprise value | 43.43M | 41.63M | 36.59M | 12.88M | 8.66M | |
| P/E ratio | -28.6 | -18.86 | 48.8 | -4.01 | -14.46 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -217.62 | -50.87 | 301.44 | -152.92 | -58.29 | |
| PFCF ratio | -217.62 | -50.87 | 301.44 | -122.3 | -58.29 | |
| P/B Ratio | 4 | 3.94 | 3.48 | 1.11 | -3.52 | |
| PTB ratio | 4 | 3.94 | 3.48 | 1.11 | -3.52 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -92.27 | -77.01 | 288.05 | -22.18 | -70.34 | |
| EV to operating cash flow | -220.13 | -52.48 | 313.49 | -170.63 | -70.91 | |
| EV to free cash flow | -220.13 | -52.48 | 313.49 | -136.46 | -70.91 | |
| Earnings yield | -0.01 | -0.01 | 0.01 | -0.06 | -0.02 | |
| Free cash flow yield | 0 | -0.02 | 0 | -0.01 | -0.02 | |
| Debt to equity | 0.05 | 0.13 | 0.14 | 0.13 | -0.77 | |
| Debt to assets | 0.04 | 0.11 | 0.11 | 0.11 | 3.12 | |
| Net debt to EBITDA | -1.05 | -2.37 | 11.07 | -2.3 | -12.52 | |
| Current ratio | 0.14 | 0.11 | 0.11 | 0.1 | 0.08 | |
| Interest coverage | -12.39K | -92.7 | 0.36 | 0 | 0 | |
| Income quality | 0.2 | 1.48 | -5.9 | 0.1 | 0.9 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.98 | 0.98 | 0.98 | 0.98 | 0.6 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0.25 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | -4.4 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.01 | 0.01 | 0.01 | 0.02 | 0 | |
| ROIC | -0.03 | -0.05 | -0.01 | -0.05 | 0.26 | |
| Return on tangible assets | -2.04 | -2.79 | 0.76 | -3.11 | -0.62 | |
| Graham Net | 0 | 0 | 0 | 0 | 0 | |
| Working capital | -1.12M | -1.63M | -1.89M | -2.1M | -2.32M | |
| Tangible asset value | -1.25M | -1.78M | -2.04M | -2.1M | -2.32M | |
| Net current asset value | -1.25M | -1.78M | -2.04M | -2.1M | -2.32M | |
| Invested capital | 0.05 | 0.13 | 0.14 | 0.13 | -0.77 | |
| Average receivables | 24.31K | 35.59K | 36.67K | 704 | -22.82K | |
| Average payables | 568.78K | 617.86K | 640.24K | 644.9K | 700.06K | |
| Average inventory | 931 | 930 | 976.5 | 997.5 | 992 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.03 | -0.05 | 0.02 | -0.07 | 0.06 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
ABTI Frequently Asked Questions
What is Alterola Biotech, Inc. stock symbol ?
Alterola Biotech, Inc. is a GB stock and trading under the symbol ABTI
What is Alterola Biotech, Inc. stock quote today ?
Alterola Biotech, Inc. stock price is $0.0054 today.
Is Alterola Biotech, Inc. stock public?
Yes, Alterola Biotech, Inc. is a publicly traded company.
Company Profile
- Volume Average 5.85K
- Market Capitalization 7.47M
- CEO Mr. David John Hitchcock O.B.E.
- Headquarters Birkenhead,GB
- IPO Date 2010-05-05
-
Website
https://alterola-abti.com 
Alterola Biotech, Inc., a pharmaceutical company, engages in the development of cannabinoid and cannabinoid-like molecules. It focuses on the development of regulated human and animal health pharmaceuticals and regulated food products; production of active pharmaceutical ingredients and food-grade ingredients; and formulation and drug delivery for improved bioavailability, solubility, and stability. The company is based in Birkenhead, the United Kingdom.
